Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 20 for:    evlp

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03382977
Recruitment Status : Recruiting
First Posted : December 26, 2017
Last Update Posted : December 3, 2019
Sponsor:
Information provided by (Responsible Party):
VBI Vaccines Inc.

Brief Summary:
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with Recurrent GBM.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Biological: VBI-1901 Phase 1 Phase 2

Detailed Description:
This is a two-part, dose-escalation study to define the safety, tolerability, and optimal dose level of candidate GBM vaccine VBI-1901 with subsequent extension of optimal dose level in recurrent GBM subjects. Subjects in the dose escalation (Part A of trial) as well as extension phase of the trial (Part B) will continue to receive vaccine every 4 weeks until tumor progression per iRANO criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

3+ 3 Dose Escalation

Therapeutic Vaccine: VBI-1901

The vaccine is formulated with GM-CSF and administered intradermally (ID) or AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Masking: None (Open Label)
Masking Description: None, open-label Allocation (FDAAA)
Primary Purpose: Treatment
Official Title: A Two-part, Phase I/IIA Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects
Actual Study Start Date : December 6, 2017
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dose Level 1
VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
Biological: VBI-1901
The vaccine is formulated with GM-CSF and administered intradermally (ID) or AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Experimental: Dose Level 2
VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
Biological: VBI-1901
The vaccine is formulated with GM-CSF and administered intradermally (ID) or AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Experimental: Dose Level 3
VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
Biological: VBI-1901
The vaccine is formulated with GM-CSF and administered intradermally (ID) or AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Experimental: Dose Level 4
VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.
Biological: VBI-1901
The vaccine is formulated with GM-CSF and administered intradermally (ID) or AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Experimental: Dose Level 5
VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection
Biological: VBI-1901
The vaccine is formulated with GM-CSF and administered intradermally (ID) or AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.




Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) occurring during Part A of the study and the occurrence of AEs during each treatment cycle in both Part A and Part B of the study [ Time Frame: For DLT in Part A, analysis will be based on the occurrence of Adverse Events (AEs) from first injection at Day 1 to Day 14. Analysis of AEs in Part A and Part B will be based on the occurrence of AEs until 28 days post injection ]
    Dose limiting toxicity (DLT) occurring during Part A and the occurrence of AEs in Part A and B of the study


Secondary Outcome Measures :
  1. Immunogenicity and optimal vaccine-induced immunity-serum IgG anti-gB antibodies (Part A and B) [ Time Frame: Baseline and 2 weeks after each dose of vaccine until tumor progression or toxicity ]
    Serum IgG anti-gB antibody titers in baseline and post vaccination samples.

  2. Cellular immunity against HCMV gB and pp65 antigens (Part A and B) [ Time Frame: Baseline and 2 weeks after each dose of vaccine ]
    Cellular immunity against HCMV gB and pp65 antigens using IFN‐γ and IL‐5 ELISPOT assessed at baseline and 2 weeks after each vaccination. Results will be provided as frequencies of IFN‐γ and IL‐5 spots/3x105 peripheral blood mononuclear cells (PBMCs) post HCMV stimulation at baseline and after each vaccination.

  3. Changes in frequencies of myeloid suppressor cells and regulatory T cells (Part A and B) [ Time Frame: Baseline and 2 weeks after each dose of vaccine ]
    Additional exploratory immunological measurements, including changes in the frequency of myeloid suppressor cells and regulatory T cells (Tregs)

  4. Progression free survival (PFS) (Part A and B) [ Time Frame: From the date of first dose to date of progression or death, as well as at 6 months and 12 months ]
    Progression free survival (PFS) from date of first dose to date of progression (according to iRANO criteria) or death, as well as at 6 months and 12 months. Subject who stop treatment for causes other than progression may be censored if other therapy is initiated or if regular assessments for assessing progression are no longer available.

  5. Overall survival (OS) (Part A and B) [ Time Frame: 6 months and 12 months from date of first dose ]
    Overall survival (OS) at 6 months and 12 months from date of first dose

  6. Median overall survival (Part A and B) [ Time Frame: Date of first dose to date of death from any cause, assessed up to 18 months ]
    Median overall survival

  7. Reduction in steroid use compared to baseline (Part A and B) [ Time Frame: Baseline to study completion, an average of 12 months ]
    Reduction in steroid use compared to baseline

  8. Change in quality of life (QOL questionnaire) compared to baseline (Part A and B) [ Time Frame: Baseline to study completion, an average of 12 months ]
    Change in quality of life (QOL questionnaire) compared to baseline

  9. Immunogenicity of the optimal dose of VBI-1901 formulated with either GM-CSF or AS01B adjuvants (Part B). [ Time Frame: Baseline and 2 weeks after each dose of vaccine until tumor progression or toxicity ]
    Part B of the Study will evaluate the safety, immunogenicity and patient survival at an optimal dose of VBI-1901 as outlined in Part A. A correlation with clinical outcomes listed above in addition to tumor response will also be determined.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

PART A DOSE ESCALATION

Inclusion Criteria: Part A Dose Escalation

  1. 18-70 years of age
  2. Histologically confirmed WHO grade IV glioblastoma
  3. Unequivocal evidence of a tumor recurrence (any number of recurrences) or progression after an initial treatment regimen (prior to enrollment on this study) as assessed by MRI of the brain with and without contrast within 30 days prior to the initiation of injections of VBI-1901. An initial therapy requires surgery and radiation therapy, with or without temozolomide. In addition, alternate therapy (with or instead of temozolomide) is permitted as part of initial therapy.
  4. Recovery from the effects of surgery.
  5. Corticosteroid (dexamethasone or equivalent) dosage ≤ 4mg daily that has been stable or decreasing for at least 5 days.
  6. Recovery from prior therapy toxicity defined as resolution of all treatment-related adverse events (AEs) to Grade ≤ 1 or pre-treatment baseline (except alopecia).
  7. Karnofsky performance status (KPS) score ≥ 70%.
  8. Adequate organ function, including the following:

    1. Absolute neutrophil count (ANC) ≥ 1,000/μL, platelets ≥ 100,000/μL
    2. Serum creatinine < 1.5 × the upper limit of normal (ULN)
    3. Bilirubin < 1.5 × ULN
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 × ULN
  9. Women of childbearing potential: negative urine pregnancy test within 14 days prior to the start of VBI-1901 treatment.
  10. Female subjects of childbearing potential and sexually active male subjects must agree to use an acceptable form of contraception for heterosexual activity (i.e., oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for >30 days before Screening, during the study, and for 60 days after the last dose of study drug).
  11. Female subjects without childbearing potential (spontaneous amenorrhea for > 12 months or surgically sterilized by tubal ligation, hysterectomy, or bilateral oophorectomy > 6 months before Screening) are eligible for inclusion without contraceptive use restriction.
  12. Able and willing to comply with protocol requirements in the opinion of the Investigator, including being able to have an MRI.
  13. Written consent has been obtained.
  14. Tumor specimen available for central pathological review.

Exclusion Criteria: Part A Dose Escalation

  1. Contrast-enhancing residual tumor that is associated with either diffuse sub-ependymal or leptomeningeal dissemination.
  2. Requirement of systemic corticosteroid therapy > 4 mg/day of dexamethasone or equivalent or requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of VBI-1901 treatment.
  3. Evidence of HCMV viremia in serum of > 18,200 (4.3Log10) IU/mL using FDA approved COBAS® AmpliPrep/COBAS® TaqMan® HCMV test (Roche).
  4. Surgical resection or major surgical procedure within 4 days prior to the start of VBI-1901, or stereotactic biopsy within 7 days prior to the start of VBI-1901.
  5. Active infection requiring intravenous antibiotics or antiviral.
  6. History of cancer (other than GBM or prostate) within the past 2 years that could negatively impact survival and/or potentially confound tumor response assessments within this study.
  7. Known immunosuppressive disease or active systemic autoimmune disease such as systemic lupus erythematosus, human immunodeficiency virus infection, Hepatitis B virus or Hepatitis C virus infections. Subjects with vitiligo, type 1 diabetes mellitus, hypothyroidism due to autoimmune condition only requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  8. Immunosuppressive agent within 4 weeks prior to the start of VBI-1901 treatment.
  9. Evidence of intra-tumoral or peri-tumoral hemorrhage on baseline, other than those that are ≤Grade 1 and either post-operative or stable on at least 2 consecutive MRI scans.
  10. Any condition which in the investigator's opinion makes the subject unsuitable for study participation.
  11. Lack of family or social support structure that would preclude continued participation in the study.

PART B OPTIMAL DOSE

Inclusion Criteria: Part B Optimal Dose

  1. 18-70 years of age.
  2. Histologically confirmed WHO grade IV glioblastoma.
  3. Unequivocal evidence of a first tumor recurrence with measurable disease, of an area no greater than 400 mm2, which may include patients with resected first recurrence tumor after an initial treatment regimen (prior to enrollment on this study) consisting of surgical intervention (tumor resection) and radiation, with or without temozolomide chemotherapy (depending on the MGMT methylation status), as assessed by MRI of the brain with and without contrast within 30 days prior to the initiation of injections of VBI-1901. In addition, alternate chemotherapy (with or instead of temozolomide) is permitted as part of initial therapy.
  4. At least 12 weeks since radiotherapy treatment and/or 23 days after chemotherapy prior to first dose of VBI-1901.
  5. Recovery from the effects of surgery.
  6. Corticosteroid (dexamethasone or equivalent) dosage ≤ 4mg daily that has been stable or decreasing for at least 5 days.
  7. Recovery from prior therapy toxicity, defined as resolution of all treatment-related adverse events (AEs) to Grade ≤ 1 or pre-treatment baseline (except alopecia).
  8. Karnofsky performance status (KPS) score ≥ 70%.
  9. Adequate organ function, including the following:

    1. Absolute neutrophil count (ANC) ≥ 1,000/μL, platelets ≥ 100,000/μL; absolute lymphocyte count ≥ 500/uL;
    2. Serum creatinine < 1.5 × the upper limit of normal (ULN);
    3. Bilirubin < 1.5 × ULN;
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 × ULN.
  10. Women of childbearing potential must have a negative urine pregnancy test within 14 days prior to the start of VBI-1901 treatment.
  11. Female subjects of childbearing potential and sexually active male subjects must agree to use an acceptable form of contraception for heterosexual activity (i.e., oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for > 30 days before Screening, during the study, and for 60 days after the last dose of study drug).
  12. Female subjects without childbearing potential (spontaneous amenorrhea for > 12 months or surgically sterilized by tubal ligation, hysterectomy, or bilateral oophorectomy > 6 months before Screening) are eligible for inclusion without contraceptive use restriction.
  13. Able and willing to comply with protocol requirements, in the opinion of the Investigator.
  14. Written consent has been obtained.
  15. Tumor specimen available for central pathological review.

Exclusion Criteria: Part B Optimal Dose

  1. Contrast-enhancing residual tumor that is any of the following:

    1. An area greater than 400mm2;
    2. Multi-focal (defined as two separate areas of contrast enhancement measuring at least 1 cm in 2 planes that are not contiguous on either fluid-attenuated inversion recovery (FLAIR) or T2 sequences);
    3. Associated with either diffuse sub-ependymal or leptomeningeal dissemination.
  2. IDH1/2 has been proven to be mutated by IHC or PCR or if recurrent GBM was previously a lower grade glioma and wildtype IDH1/2 status has not been confirmed.
  3. Requirement of systemic corticosteroid therapy > 4 mg/day of dexamethasone or equivalent or requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of VBI-1901 treatment.
  4. Evidence of HCMV viremia in plasma of >18,200 (4.3log10) IU/mL using FDA approved COBAS® AmpliPrep/COBAS® TaqMan® HCMV test (Roche).
  5. Prior treatment involving immunotherapy, including oncolytic viruses, therapeutic vaccination, or biologics (e.g. monoclonal antibodies, such as bevacizumab) presumed to have immunomodulatory effects.
  6. Surgical resection or major surgical procedure within 14 days prior to the start of VBI-1901, or stereotactic biopsy within 14 days prior to the start of VBI-1901.
  7. Radiation therapy, local therapy (except for surgical re-resection), or systemic therapy following first recurrence/progressive disease. Excluded local therapies include stereotactic radiation boost, implantation of carmustine biodegradable wafers (Gliadel), intratumoral or convection- enhanced delivery administered agents, etc.
  8. Concurrent therapy with Optune® or use within 1 week of start of treatment with VBI-1901.
  9. Active infection requiring intravenous antibiotics or antivirals.
  10. History of cancer (other than GBM or prostate) within the past 2 years that has metastatic or local recurrence potential and could negatively impact survival and/or potentially confound tumor response assessments within this study.
  11. Known immunosuppressive disease or active systemic autoimmune disease such as systemic lupus erythematosus, human immunodeficiency virus infection, Hepatitis B virus or Hepatitis C virus infections. Subjects with vitiligo, type 1 diabetes mellitus, hypothyroidism due to autoimmune condition only requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  12. Immunosuppressive agent within 4 weeks prior to the start of VBI-1901 treatment.
  13. Any severe adverse event or allergy suspected or attributed to the shingles vaccines that contains AS01B components.
  14. Evidence of intra- or peri-tumoral hemorrhage on baseline MRI scan, other than those that are ≤Grade 1 and either post-operative or stable on at least 2 consecutive MRI scans.
  15. Any condition which in the investigator's opinion makes the subject unsuitable for study participation.
  16. Lack of family or social support structure that would preclude continued participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03382977


Contacts
Layout table for location contacts
Contact: Kara B Langer, BSc (508) 667-8755 kara.langer@veristat.com
Contact: Bebi Yassin-Rajkumar, MS 866-574-7034 BYassin-Rajkumar@vbivaccines.com

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Edwin Nunez       ENUNEZ2@mgh.harvard.edu   
Principal Investigator: Deborah Forst, MD         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Nicole Devaney       NicoleD_Devaney@DFCI.HARVARD.EDU   
Principal Investigator: Patrick Wen, MD         
United States, New York
The Neurological Institute of New York Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Natalie Busby    212-305-8487    nb2718@cumc.columbia.edu   
Principal Investigator: Andrew B Lassman, MD         
Sponsors and Collaborators
VBI Vaccines Inc.
Investigators
Layout table for investigator information
Study Director: Francisco Diaz-Mitoma, MD Variation Biotechnologies Inc.

Layout table for additonal information
Responsible Party: VBI Vaccines Inc.
ClinicalTrials.gov Identifier: NCT03382977     History of Changes
Other Study ID Numbers: VBI-1901-01
First Posted: December 26, 2017    Key Record Dates
Last Update Posted: December 3, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by VBI Vaccines Inc.:
GBM
Glioblastoma
eVLP
VBI-1901
vaccine
immunotherapy
CMV
CNS
Brain
Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Vaccines
Immunologic Factors
Physiological Effects of Drugs